세계의 고환암 시장 보고서(2025년)

Testicular Cancer Global Market Report 2025

US $ 4,490 ￦ 6,183,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,938,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,692,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

고환암 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 예측 기간 동안 예상되는 성장은 고환암 진단 증가, 질병의 유병률 증가, 광범위한 치료 옵션, 표적 치료의 채택 증가와 같은 요인에 기인 할 수 있습니다. 이 기간에 예상되는 주요 동향으로는 치료 선택지의 발전, 선진 의료시설의 개발, 지속적인 연구 개발, 표적약의 창출, 임상시험의 진전 등을 들 수 있습니다.

고환암 시장의 성장은 고환암 진단 건수 증가에 의해 견인될 것으로 예측됩니다. 검진의 빈도 증가로 인한 것으로 생각됩니다. 고환암 시장은 연구에 자금을 제공하고 진단 도구를 진보시켜 조기 발견을 촉진하는 계발 캠페인을 지원함으로써 이 성장에 공헌하고 있습니다. 예를 들어 2024년 7월 호주에 본사를 둔 비영리 단체인 빅토리아 암 협의회는 2022년 40세 미만 남성의 고환암 진단 건수가 160건으로 40-49세 연령대의 37건에 비해 훨씬 더 많았다는 보고서를 발표했습니다.

고환암 시장의 주요 기업은 CLDN6 양성 부인과암과 고환암을 표적으로 하는 세포 인게이지드·바이스페시픽 항체 등의 혁신적인 제품의 개발에 주력하고 있습니다. 맞추기 위해 설계되었으며, 면역세포가 암세포와 질환세포를 활성화하고 파괴하는 것을 가능하게 합니다. 예를 들어 2024년 5월, 미국에 본사를 둔 바이오 제약 회사인 Context Therapeutics는 미국 식품의약국(FDA)이 CLDN6 x CD3 T 세포 결합 이중특이항체인 CTIM-76에 대한 임상시험용 신약(IND) 신청을 승인했다고 발표했습니다. 이 승인을 통해 회사는 CLDN6 양성 부인암 및 고환암 환자를 대상으로 CTIM-76을 평가하기 위한 임상 1상 시험을 시작할 수 있게 되었습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 고환암 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 고환암 시장 : 성장률 분석
• 세계의 고환암 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 고환암 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 고환암 전체 시장(TAM)

제6장 시장 세분화

• 세계의 고환암 시장 : 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 수술
• 화학요법
• 방사선요법
• 면역요법
• 표적요법
• 세계의 고환암 시장 : 조직학별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세미종
• 비세미종
• 혼합
• 세계의 고환암 시장 : 제품별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 정제
• 캡슐
• 크림
• 세계의 고환암 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 경구
• 국소
• 세계의 고환암 시장 : 최종 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 클리닉
• 세계의 고환암 시장 : 수술 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 고환 절제술
• 복막 림프절 절제술(RPLND)
• 세계의 고환암 시장 : 화학요법 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 백금 기반 화학요법
• 화학요법(BEP 요법)
• 세계의 고환암 시장 : 방사선요법 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 외부 빔 방사선
• 후복막 방사선
• 세계의 고환암 시장 : 면역요법 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 면역관문억제제
• 암 백신
• 세계의 고환암 시장 : 표적요법 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 티로신 키나아제 억제제
• 단일클론항체

제7장 지역별/국가별 분석

• 세계의 고환암 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 고환암 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 고환암 시장 : 경쟁 구도
• 고환암 시장 : 기업 프로파일
  • Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Bristol-Myers Squibb Company : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Abbott Laboratories : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Fresenius Kabi : 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• BioNTech SE
• Teva Pharmaceuticals Industries Ltd.
• Baxter International Inc.
• Mount Sinai Health System
• UCLA Medical Center
• Duke University Medical Center
• Accord Healthcare Limited
• UC San Diego Health
• Venus Remedies Limited
• Florencia Healthcare
• Hirslanden Group
• Ziopharm Oncology Inc.
• Beijing Biostar Pharmaceuticals Co. Ltd.
• 베타 Drugs Ltd.
• Scripps Health

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 고환암 시장(2029년) : 새로운 기회를 제공하는 국가
• 고환암 시장(2029년) : 새로운 기회를 제공하는 부문
• 고환암 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

KTH

영문 목차

영문목차

Testicular cancer is a type of cancer that begins in the testicles, which are part of the male reproductive system. It most commonly affects young men and is highly treatable, particularly when detected early. Although it is relatively rare, testicular cancer is one of the most frequent cancers among young men, especially those aged 15 to 35. It often presents as a lump or swelling in one testicle, occasionally accompanied by pain or discomfort.

The primary treatment options for testicular cancer include surgery, chemotherapy, radiotherapy, immunotherapy, and targeted therapy. Surgery, especially orchiectomy, involves the removal of the affected testicle to prevent the cancer from spreading, contributing to the growth of the surgical instruments market due to the ongoing demand for this procedure. Treatment depends on the histological classification of the cancer, which includes seminoma, non-seminoma, and mixed types. Available product forms include tablets, capsules, and creams, with administration routes being primarily oral or topical. These treatments are utilized in various settings, including hospitals and clinics.

The testicular cancer market research report is one of a series of new reports from The Business Research Company that provides testicular cancer market statistics, including the testicular cancer industry global market size, regional shares, competitors with the testicular cancer market share, detailed testicular cancer market segments, market trends, and opportunities, and any further data you may need to thrive in the testicular cancer industry. This testicular cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The testicular cancer market size has grown strongly in recent years. It will grow from $3.43 billion in 2024 to $3.71 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth observed during the historic period can be attributed to factors such as heightened awareness about testicular cancer, an increase in the prevalence of risk factors, a rising incidence of testicular cancer, and a growing demand for diagnostic services.

The testicular cancer market size is expected to see strong growth in the next few years. It will grow to $4.97 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth projected for the forecast period can be attributed to factors such as the increasing diagnosis of testicular cancer, a rising prevalence of the disease, a broader range of treatment options, and a growing adoption of targeted therapies. Key trends expected during this period include advancements in treatment options, the development of advanced healthcare facilities, continued research and development, the creation of targeted medications, and progress in clinical trials.

The growth of the testicular cancer market is expected to be driven by the rising number of testicular cancer diagnoses. Testicular cancer occurs in the male testicles and is usually characterized by painless lumps or swelling. The increase in diagnoses may be attributed to greater awareness, improved diagnostic methods, and more frequent self-examinations, along with potential environmental and lifestyle factors. The testicular cancer market contributes to this growth by funding research, advancing diagnostic tools, and supporting awareness campaigns that promote early detection. For example, in July 2024, the Cancer Council Victoria, an Australia-based non-profit organization, published a report showing that in 2022, the number of testicular cancer diagnoses among males under 40 was significantly higher, with 160 cases, compared to just 37 cases in the 40-49 age group. This highlighted a notable disparity in diagnoses between younger and middle-aged men. As a result, the increasing diagnosis of testicular cancer is driving the growth of the testicular cancer market.

Leading companies in the testicular cancer market are focusing on developing innovative products, such as cell-engaging bispecific antibodies, to target CLDN6-positive gynecologic and testicular cancers. A cell-engaging bispecific antibody is designed to bind to two distinct targets, enabling immune cells to activate and destroy cancer or diseased cells. For example, in May 2024, Context Therapeutics Inc., a biopharmaceutical company based in the US, announced that the U.S. Food and Drug Administration (FDA) had approved its Investigational New Drug (IND) application for CTIM-76, a CLDN6 x CD3 T cell-engaging bispecific antibody. This approval allows the company to begin a Phase 1 clinical trial to assess CTIM-76 in patients with CLDN6-positive gynecologic and testicular cancers. The trial will focus on dose escalation and expansion to evaluate the drug's safety, efficacy, and pharmacokinetics.

In September 2022, CellOrigin Biotech Co., Ltd., a biotechnology company based in China, formed a collaboration with Shandong Qilu Pharmaceutical Co., Ltd. The partnership aims to develop, manufacture, and commercialize off-the-shelf iPSC-derived chimeric antigen receptor macrophages (CAR-iMAC) for cancer treatment. Shandong Qilu Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company that specializes in treatments for various types of cancer, including testicular cancer.

Major players in the testicular cancer market are Pfizer Inc., Merck & Co. Inc., Bristol-Myers Squibb Company, Abbott Laboratories, Fresenius Kabi, BioNTech SE, Teva Pharmaceuticals Industries Ltd., Baxter International Inc., Mount Sinai Health System, UCLA Medical Center, Duke University Medical Center, Accord Healthcare Limited, UC San Diego Health, Venus Remedies Limited, Florencia Healthcare, Hirslanden Group, Ziopharm Oncology Inc., Beijing Biostar Pharmaceuticals Co. Ltd., Beta Drugs Ltd., Scripps Health.

North America was the largest region in the testicular cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in testicular cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the testicular cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The testicular cancer market consists of revenues earned by entities by providing services such as early detection and screening services, supportive services, biopsy procedures, research, and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. The testicular cancer market also includes sales of drugs, surgical products, biomarker testing kits, and diagnostic imaging devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Testicular Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on testicular cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for testicular cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The testicular cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Surgery; Chemotherapy; Radiotherapy; Immunotherapy; Targeted Therapy
• 2) By Histology: Seminoma; Non-Seminoma; Mixed
• 3) By Product: Tablet; Capsule; Creams
• 4) By Route Of Administration: Oral; Topical
• 5) By End-use: Hospitals; Clinics
• Subsegments:
• 1) By Surgery: Orchiectomy; Retroperitoneal Lymph Node Dissection (RPLND)
• 2) By Chemotherapy: Platinum-Based Chemotherapy; Chemotherapy Regimens (BEP regimen)
• 3) By Radiotherapy: External Beam Radiation; Retroperitoneal Radiation
• 4) By Immunotherapy: Immune Checkpoint Inhibitors; Cancer Vaccines
• 5) By Targeted Therapy: Tyrosine Kinase Inhibitors; Monoclonal Antibodies
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Bristol-Myers Squibb Company; Abbott Laboratories; Fresenius Kabi
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Testicular Cancer Market Characteristics

3. Testicular Cancer Market Trends And Strategies

4. Testicular Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Testicular Cancer Growth Analysis And Strategic Analysis Framework

• 5.1. Global Testicular Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Testicular Cancer Market Growth Rate Analysis
• 5.4. Global Testicular Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Testicular Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Testicular Cancer Total Addressable Market (TAM)

6. Testicular Cancer Market Segmentation

• 6.1. Global Testicular Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Chemotherapy
• Radiotherapy
• Immunotherapy
• Targeted Therapy
• 6.2. Global Testicular Cancer Market, Segmentation By Histology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Seminoma
• Non-Seminoma
• Mixed
• 6.3. Global Testicular Cancer Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablet
• Capsule
• Creams
• 6.4. Global Testicular Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Topical
• 6.5. Global Testicular Cancer Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• 6.6. Global Testicular Cancer Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Orchiectomy
• Retroperitoneal Lymph Node Dissection (RPLND)
• 6.7. Global Testicular Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Platinum-Based Chemotherapy
• Chemotherapy Regimens (BEP regimen)
• 6.8. Global Testicular Cancer Market, Sub-Segmentation Of Radiotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation
• Retroperitoneal Radiation
• 6.9. Global Testicular Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immune Checkpoint Inhibitors
• Cancer Vaccines
• 6.10. Global Testicular Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tyrosine Kinase Inhibitors
• Monoclonal Antibodies

7. Testicular Cancer Market Regional And Country Analysis

• 7.1. Global Testicular Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Testicular Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Testicular Cancer Market

• 8.1. Asia-Pacific Testicular Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Testicular Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Testicular Cancer Market, Segmentation By Histology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Testicular Cancer Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Testicular Cancer Market

• 9.1. China Testicular Cancer Market Overview
• 9.2. China Testicular Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Testicular Cancer Market, Segmentation By Histology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Testicular Cancer Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Testicular Cancer Market

• 10.1. India Testicular Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Testicular Cancer Market, Segmentation By Histology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Testicular Cancer Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Testicular Cancer Market

• 11.1. Japan Testicular Cancer Market Overview
• 11.2. Japan Testicular Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Testicular Cancer Market, Segmentation By Histology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Testicular Cancer Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Testicular Cancer Market

• 12.1. Australia Testicular Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Testicular Cancer Market, Segmentation By Histology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Testicular Cancer Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Testicular Cancer Market

• 13.1. Indonesia Testicular Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Testicular Cancer Market, Segmentation By Histology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Testicular Cancer Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Testicular Cancer Market

• 14.1. South Korea Testicular Cancer Market Overview
• 14.2. South Korea Testicular Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Testicular Cancer Market, Segmentation By Histology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Testicular Cancer Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Testicular Cancer Market

• 15.1. Western Europe Testicular Cancer Market Overview
• 15.2. Western Europe Testicular Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Testicular Cancer Market, Segmentation By Histology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Testicular Cancer Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Testicular Cancer Market

• 16.1. UK Testicular Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Testicular Cancer Market, Segmentation By Histology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Testicular Cancer Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Testicular Cancer Market

• 17.1. Germany Testicular Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Testicular Cancer Market, Segmentation By Histology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Testicular Cancer Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Testicular Cancer Market

• 18.1. France Testicular Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Testicular Cancer Market, Segmentation By Histology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Testicular Cancer Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Testicular Cancer Market

• 19.1. Italy Testicular Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Testicular Cancer Market, Segmentation By Histology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Testicular Cancer Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Testicular Cancer Market

• 20.1. Spain Testicular Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Testicular Cancer Market, Segmentation By Histology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Testicular Cancer Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Testicular Cancer Market

• 21.1. Eastern Europe Testicular Cancer Market Overview
• 21.2. Eastern Europe Testicular Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Testicular Cancer Market, Segmentation By Histology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Testicular Cancer Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Testicular Cancer Market

• 22.1. Russia Testicular Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Testicular Cancer Market, Segmentation By Histology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Testicular Cancer Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Testicular Cancer Market

• 23.1. North America Testicular Cancer Market Overview
• 23.2. North America Testicular Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Testicular Cancer Market, Segmentation By Histology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Testicular Cancer Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Testicular Cancer Market

• 24.1. USA Testicular Cancer Market Overview
• 24.2. USA Testicular Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Testicular Cancer Market, Segmentation By Histology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Testicular Cancer Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Testicular Cancer Market

• 25.1. Canada Testicular Cancer Market Overview
• 25.2. Canada Testicular Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Testicular Cancer Market, Segmentation By Histology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Testicular Cancer Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Testicular Cancer Market

• 26.1. South America Testicular Cancer Market Overview
• 26.2. South America Testicular Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Testicular Cancer Market, Segmentation By Histology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Testicular Cancer Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Testicular Cancer Market

• 27.1. Brazil Testicular Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Testicular Cancer Market, Segmentation By Histology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Testicular Cancer Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Testicular Cancer Market

• 28.1. Middle East Testicular Cancer Market Overview
• 28.2. Middle East Testicular Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Testicular Cancer Market, Segmentation By Histology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Testicular Cancer Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Testicular Cancer Market

• 29.1. Africa Testicular Cancer Market Overview
• 29.2. Africa Testicular Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Testicular Cancer Market, Segmentation By Histology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Testicular Cancer Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Testicular Cancer Market Competitive Landscape And Company Profiles

• 30.1. Testicular Cancer Market Competitive Landscape
• 30.2. Testicular Cancer Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Fresenius Kabi Overview, Products and Services, Strategy and Financial Analysis

31. Testicular Cancer Market Other Major And Innovative Companies

• 31.1. BioNTech SE
• 31.2. Teva Pharmaceuticals Industries Ltd.
• 31.3. Baxter International Inc.
• 31.4. Mount Sinai Health System
• 31.5. UCLA Medical Center
• 31.6. Duke University Medical Center
• 31.7. Accord Healthcare Limited
• 31.8. UC San Diego Health
• 31.9. Venus Remedies Limited
• 31.10. Florencia Healthcare
• 31.11. Hirslanden Group
• 31.12. Ziopharm Oncology Inc.
• 31.13. Beijing Biostar Pharmaceuticals Co. Ltd.
• 31.14. Beta Drugs Ltd.
• 31.15. Scripps Health

32. Global Testicular Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Testicular Cancer Market

34. Recent Developments In The Testicular Cancer Market

35. Testicular Cancer Market High Potential Countries, Segments and Strategies

• 35.1 Testicular Cancer Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Testicular Cancer Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Testicular Cancer Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료